Nuclear medicine in pneumology

被引：0

作者：

Menzel C. ^{[1
]}

机构：

[1] Praxis für Nuklearmedizin, Dr. Horst Schmidt Klinik, 65199 Wiesbaden

来源：

Der Pneumologe | 2013年 / 10卷 / 3期

关键词：

Lung cancer; Lung function; Positron emission tomography- computed tomography; Scintigraphy; Tumor staging;

D O I：

10.1007/s10405-013-0680-9

中图分类号：

学科分类号：

摘要：

In clinical pneumology there is an established role in nuclear medicine for positron emission tomography-computed tomography (PET-CT) using 18-fluorodeoxyglucose (18-FDG). It is frequently applied for staging and restaging of non-small cell lung cancer (NSCLC) and shows recognized benefits for patients as a non-invasive method for whole body staging. Further indications are the assessment of dignity and differentiation of suspicious lung nodules as well as in small cell lung cancer (SCLC) to confirm limited disease if a curative approach is still intended. Conventional nuclear medicine techniques of interest in pneumology include lung perfusion and ventilation diagnostic methods as well as bone scintigraphy. Lung perfusion studies are used to detect pulmonary embolisms and to assess postoperative lung function in correlation to preoperative forced expiratory volume (FEV1). Bone scintigraphy is needed as the basic diagnostic investigation to detect or rule out and monitor therapy control of skeletal metastases. © 2013 Springer-Verlag Berlin Heidelberg.

引用

页码：205 / 218

页数：13

共 17 条

[1]

Agarwal M., Brahmanday G., Bajaj S.K., Et al., Revisiting the prognostic value of preoperative (18)F-fluoro-2- deoxyglucose ((18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC, Eur J Nucl Med Mol Imaging, 37, pp. 691-698, (2010)

[2]

Bolukbas S., Baierlein S.A., Schirren J., Lung-cancer staging with PET, NEJM, 15, (2009)

[3]

Brink I., Schumacher T., Mix M., Et al., Impact of (18F)FDG-PET on the primary staging of small-cell lung cancer, Eur J Nucl Med Mol Imaging, 31, pp. 1614-1620, (2004)

[4]

Cuaron J., Dunphy M., Rimner A., Role of FDG-PET scans in staging, response assessment, and follow-up care for non-small cell lung cancer, Front Oncol, 2, (2012)

[5]

Davison J., Mercier G., Russo G., Et al., PET-based primary tumor volumetric parameters and survival of patients with non-small cell lung carcinoma, AJR Am J Roentgenol, 200, pp. 635-640, (2013)

[6]

De Wever W., Ceyssens S., Mortelmans L., Et al., Additional value of PET-CT in the staging of lung cancer: Comparison with CT alone, PET alone and visual correlation of PET and CT, Eur J Radiol, 17, pp. 23-32, (2007)

[7]

Hellwig D., Ukena D., Paulsen F., Et al., Meta-analysis of the efficacy of positron emission tomography with F18-fluorodeoxyglucose in lung tumors, Penumologie, 55, pp. 367-377, (2001)

[8]

Hoekstra C.J., Stroobants S.G., Smit E.F., Et al., Prognostic relevance of response evaluation using (18F)-2-fluoro-2-deoxy- D-glucose positron emission tomography in patients with locally advanced non-small cell lung cancer, J Clin Oncol, 20, pp. 8362-8370, (2005)

[9]

Schillaci O., Use of dual-point fluorodeoxyglucose imaging to enhance sensitivity and specificity, Semin Nucl Med, 42, pp. 267-280, (2012)

[10]

Stiles B.M., Nasar A., Mirza F., Et al., Ratio of positron emission tomography uptake to tumor size in surgically resected non-small cell lung cancer, Ann Thorac Surg, 95, pp. 397-403, (2013)

← 1 2 →